Good morning, Lou and Assaf, in New York. [Foreign language]. Lou, please go ahead. Thank you, Shimon. Good afternoon, everyone. We are very pleased to report our Q3 2025 results and share our momentum with everyone on the call. For Q3 2025, we achieved $21.1 million in revenue, which represents a 56% year-over-year growth. As well as in Q3, $8.3 million of this revenue came on a recurring basis, which represents a 55% year-over-year growth. Our gross margins were 73.7%, and we achieved an IFRS net income of $1 million. On the year from Q1 to Q3, we've achieved $58.7 million in revenue, representing a 42% year-over-year growth, as well as an IFRS net income of $1.4 million. We ended the quarter on September 30th with $26.5 million in cash, and we have performed over 667,000 treatments since commercialization. I don't have to tell anyone on the call about how challenging the marketplace is. I mean, there are many, many headwinds, both economically as well as geopolitically. If we look specifically at the U.S. market, you know, the high-growth med spa markets have been impacted most by access to capital and high interest rates. However, the core physicians, the dermatologists and plastic surgeons, that segment of the market remains resilient. We have, as a growing tailwind, the growing adoption of GLP-1 agonists, which are driving the demand exactly for what Sofwave makes, which is lifting laxity and superior toning treatments. As we look ahead, we're assuming with the interest rates being lowered, consumer spending could improve. High interest rates, again, are being lowered presently at the moment, which could provide additional access to capital and affordability. However, we do see increased competition coming into the tightening segment, the segment that we've had tremendous momentum. If we look as well as besides the GLP-1s driving the, to tighten and lift the skin, we also see the demand for energy-based volumization treatments, which offer a natural appearance. Further, most recently, in the beginning of this quarter, the end of last quarter, we had the FDA issue a warning letter on RF microneedling, as well as creating an opportunity for Sofwave in this market where we truly have the safest and the best solution. As far as the company's execution goes, we had exceptional results in Q3. We had solid execution across regions. We had momentum accelerated globally across major markets. Our brand awareness continues to extend. Our reach has reached the highest levels yet. This has driven procedure demand. Our product, the Sofwave SUPERB system, as well as the Pure Impact EMS system, we believe we're offering a superior competitive offering. Our value proposition to both the patient as well as to the provider is emerging as best in class. We see a rocket rising market demand. We see the glasses have filled, despite the overall macro conditions. We see the GLP-1s, allowing us an opportunity to have traction across every segment of the market. At the end of the day, we have a mindset and an execution platform that's allowed us to achieve exceptional growth as well as expanding profitability. As we look at the brand awareness, this is a very important aspect of the business. B2C marketing, as we all know, could be very, very expensive. However, as we do a deeper dive into the number, we see as our top line grows, our actual sales and marketing expense is being reduced as a percentage of the overall total. We have, again, in this GLP-1 segment and in lifting conversations, a 41% share of voice. This is up from the previous quarter where I spoke about this parameter. This parameter is basically a measurement of how many times you appear in the Google zero or number one slot using keyword long tail and short tail searches, putting together various word combinations related to how a consumer would search for a solution for lifting and laxity related to the major generic as well as the trade names of GLP-1s. We're up from 34% versus 10 other companies in the segment to 41% of that share. I'm going to pause on that and repeat it back again. 41% of the time we're appearing in the Google zero or number one slot versus 10 other companies. This is a commanding achievement. This is attributable to two years of hard work and SEO planning to achieve this. If we look across the board and look at how this is affecting not only our web traffic, it's also influencing very much our social media numbers as well. There's another new channel developing, which is Reddit. If we look at how the AI engines are searching now, beyond going beyond the internet and whatever native intelligence they develop, they're also looking at newer sources such as Reddit. So we're working very hard as well in this channel for patient education, discussing our scientific efforts as well as the other featural benefits across this channel as well. Lastly, on this particular slide, I'd like to mention that the PR reach is extended significantly, and we continue to win multiple industry awards, identifying Sofwave as best of breed technology. On this one slide here, everything is pointing upwards. Everything is green. Now, keep in mind in Q1 and Q2, we had the Kardashian effect in the numbers. This effect is sustainable. If we look at the engagement rate, this is the number of times someone likes, shares, or comments on a post. It actually expanded to 8.6% in Q3 from the previous record high of 8.3%. Our content is simply getting better. There's more of it. Our providers are on board, and it's really sustaining and creating a phenomena where, as we continue to try to expand the brand of Sofwave across every channel, we have significant traction. You know, what's in the numbers is very important, of course, the top line and the bottom line. I mean, that's really how we're judged by. But a very important engagement to us as we look forward in the business is the results of our 2025 customer satisfaction survey. We recently sent a survey out to all of our users in the U.S., and we had 500 verified responses. What came out of this report is an eye-opener, and I think it's a tremendous testimony to the efforts of our employees and the significant superiority of our support services, as well as onto the technology itself. 94% of the responders stated that they would recommend Sofwave to its peers. This is an outstanding number. Now, to further validate this number, we reflected as well. We took the same numbers and we employed the Bain Net Promoter Score. Now, what the Net Promoter Score has been developed by Bain and Company as a global standard to measure customer advocacy. Brands such as Tesla, brands such as Amazon and Apple employ this score. We scored, which is incredible, a score of 86%. What this measurement represents is the number of people who would recommend your product minus the number of detractors. Coming out at 86% puts us well above the aesthetic industry average of 46%. The drivers of this are the clinical results, the ease of use, and the responsiveness of our customer service. We believe this gives us the platform to continue to sustain our growth and expand our profitability. One last comment, which is the timing list of, as I mentioned before, the fact that Sofwave and its technology has no needles, no fat loss, and no compromise. It's truly a non-invasive, no downtime procedure with superior outcomes, superior results, and extraordinary safety that further is delegatable, right? This means that the plastic surgeon, the dermatologist, the nurse provider can safely delegate the treatment to anyone in the clinic who is trained and perform a procedure not only that lifts as well as decreases laxity, but it does not damage subcutaneous fat. Now, why is this important? When people are losing weight, we heard the phenomenon of Ozempic face. The last thing they need is an energy-based treatment that damages the fat further. Sofwave targets the mid dermis for precise collagen and elastin and hyaluronic acid remodeling. It's truly regenerative. We preserve the fat layers for essential youthful contours. This mechanism of action ensures optimal lifting without further hollowing or volume loss, seen with the more aggressive modalities such as RF microneedling and fractional lasers. I'll turn it now over to Shimon for further comments on the technology. Thank you very much, Lou. [Foreign language] Back to you, Lou, for a quick summary. Sofwave truly has disruptive technology or product deliveries, superior non-invasive skin treatments, and it's truly disruptive in the industry that has outdated solutions. We're achieving rapid industry adoption, 56% year-over-year growth in Q3. We didn't mention this earlier, but Q3, typically due to seasonality, is the weakest of all the four quarters, but yet we achieved 56%. We also have the momentum around our selling activity, and we have built an infrastructure which is lean and agile, which will continue to support high growth and profitability. Our broad range of FDA clearances for lifting, laxity, and wrinkle treatments, the investment we have made is now paying us dividends. We also have clearances across the body, and we have a great future as we extend our product line beyond the face into total body treatments. We have significant recurring revenue. We have a novel unique business model where we're partners with our customers. This represents over 40% of our total revenue, and we've achieved 667,000 treatments to date. Our brand awareness is expanding through our digital efforts, and we now have over 1 million followers. I'd like to thank everyone for participating in the call, and I'd like to now open it up for questions and answers. All right, thank you, Lou. The first question that we got here is regarding the FDA letter, and how do we think this is going to affect the demand for our product? People want solutions. People want solutions, and they go to a provider, and the provider recommends not only the technology that they feel is most appropriate, they recommend what they believe is going to be safe and efficacious. Clearly, consumers are going to come in now that it's hit all the major news channels and social media with questions about any RF microneedling. If one were to go to an Instagram feed right now, you'll see on any given day dozens of providers trying to explain themselves as qualified providers. I would say at this point in time, we are ambitious in terms and aggressive in terms of our go-to-marketing strategy, and we see this as ample opportunity not only for new placements where people, the providers, are looking for a different solution than what they have, as well as head-to-head opportunities where formerly we would have to face the entrenched competitor of our microneedling. Again, we see the glass as more than half full and potentially overflowing with this most recent announcement. Another question: we presented an accelerated growth over the last four quarters, and the question is, what changed, what is different in terms of the growth and the demand to the product this year compared to last year or the last two years? I think, let's step back a second and let's look at what's happened in the macro. We've seen tremendous challenges for every aesthetic company in the space, and somehow we've been able to be true to our go-to-market strategy, getting the thought leaders, the influencers, and now as we've achieved credibility there, it's now cascading into other segments of the market. On top of that, we've increased our channel to market capability by expanding our distribution footprint, both direct and indirect. Our FDA clearances, excuse me, our regulatory clearances, in certain of these markets have given us access and the ability to sell with major partners, and the brand awareness. You know, the strategy we invested in in going digital from day one is certainly paying off. So I would say we would have gotten here faster had we not been faced with some major challenges, but I would say, what we've done is we've been able to navigate better than most of our competitors. Thank you. And another question I'll take in Hebrew [Foreign language] All right, I don't see any further questions. Again, we are all available for additional questions through Eichenholz or on the phone.[Foreign language]. Thank you very much, Lou.